广东省有17家企业登陆A股，其中马可波罗、瑞立科密、悍高集团、新亚电缆在深市主板上市，广 东建科、同宇新材、优优绿能、钧崴电子、弘景光电、矽电股份、宏工科技、首航新能、太力科技、超 研股份在创业板上市，必贝特、影石创新在科创板上市，奥美森在北交所上市。上述17家企业合计募集 资金总额146.09亿元。 中国经济网北京11月4日讯（记者关婧 韩艺嘉）2025年前10月，上交所、深交所及北交所共计新增 87家上市企业，合计募集资金901.23亿元。其中主板29家企业上市，创业板有29家企业上市，科创板有 11家企业上市，北交所有18家企业上市。 从归属地来看，2025年前10月上市企业分布于18个省份、直辖市及自治区，其中江苏省有21家企业 上市，广东省有17家企业上市，浙江省有13家企业上市，上海市有6家企业上市，安徽省、山东省有5家 企业上市，湖北省有4家企业上市，北京市、江西省有3家企业上市，四川省有2家企业上市，陕西省、 辽宁省、内蒙古自治区、吉林省、黑龙江省、湖南省、福建省、河北省均有1家企业上市。 从单只个股募资金额来看，排名前五位的企业分别是华电新能、西安奕材、中策橡胶、天有为、联 合动力，募资金额 ...

Core Viewpoint - The company, Hangzhou Qian Dao Lake Sturgeon Technology Co., Ltd. (Sturgeon Technology), is making a significant move towards listing on the Hong Kong Stock Exchange after three failed attempts to go public in A-shares, highlighting its impressive profitability and the challenges it has faced, including past financial controversies [1][11][12]. Company Overview - Sturgeon Technology is the world's largest producer of caviar, having maintained the top global sales position for ten consecutive years since 2015, with a market share exceeding 30% and projected to reach 35.4% in 2024 [6][8]. - The company specializes in the artificial breeding, ecological farming, processing, and sales of sturgeon and caviar, with caviar being its core product [3][6]. Financial Performance - The financial data disclosed in the prospectus shows a significant increase in revenue from 491 million RMB in 2022 to 669 million RMB in 2024, with net profit rising from 234 million RMB to 324 million RMB during the same period [6][9]. - The company reported a gross profit margin of 66.3% and a net profit margin of 48.4% for 2024, with projections for the first half of 2025 showing even higher margins of 71.3% and 58.3%, respectively [6][9]. Sales and Market Presence - Approximately 80% of Sturgeon Technology's sales revenue comes from overseas markets, primarily through third-party brands, with significant contributions from major international airlines and high-end venues [8][9]. - The company has established a well-known caviar brand, "KALUGA QUEEN," and its products are exported to 46 countries and regions [6][9]. Challenges and Historical Context - Sturgeon Technology has faced a tumultuous path to capitalization, with three failed attempts to list on A-shares due to concerns over financial transparency and governance issues, particularly related to related-party transactions [11][12][16]. - The company has also encountered challenges from increased tariffs in the U.S. market, which accounts for about 30% of its revenue, posing potential risks to its financial performance [10][11].

Core Viewpoint - The article discusses the Hong Kong IPO application of Sturgeon Technology, the world's largest caviar producer, highlighting its impressive profitability and the challenges it faced in previous A-share IPO attempts [2][15]. Company Overview - Sturgeon Technology, established in 2003, specializes in artificial breeding, ecological farming, and processing of sturgeon and caviar products, with caviar being its core product [5][10]. - The company has maintained its position as the global leader in caviar sales for ten consecutive years since 2015, capturing over 30% of the global market share, which is projected to reach 35.4% in 2024 [7][8]. Financial Performance - Sturgeon Technology's revenue grew from 491 million RMB in 2022 to 669 million RMB in 2024, with net profit increasing from 234 million RMB to 324 million RMB during the same period [7][8]. - The company reported a gross margin of 66.3% and a net margin of 48.4% for 2024, with projections for the first half of 2025 showing a gross margin of 71.3% and a net margin of 58.3% [8][9]. Market Presence - Approximately 80% of Sturgeon Technology's sales revenue comes from international markets, primarily through third-party brands [11][12]. - The company has established a well-known caviar brand, "KALUGA QUEEN," and supplies products to major international airlines and high-end venues [10]. IPO Challenges - Sturgeon Technology has faced significant hurdles in its attempts to go public in China, with three failed A-share IPO applications due to concerns over financial transparency and governance issues [16][19]. - The company has been embroiled in financial controversies, including allegations of data manipulation related to its financial statements, which have hindered its IPO efforts [18][20].

Core Viewpoint - The upcoming IPO review period from November 3 to November 7 will feature five companies aiming to raise a total of 3.812 billion yuan [1]. IPO Companies Overview - Five companies are scheduled for IPO review: - Qilong Ocean (Shandong) aims to raise 381.889 million yuan, with a net profit of 50.67 million yuan [2][5]. - Zhixin Co., Ltd. plans to raise 1.329 billion yuan, reporting a net profit of 203.964 million yuan [2][10]. - Shaanxi Tourism intends to raise 1.555 billion yuan, with a net profit of 621.578 million yuan [2][15]. - Haiseng Medical (Zhejiang) seeks to raise 370.425 million yuan, with a net profit of 70.918 million yuan [2][20]. - Guoliang New Materials (Hebei) aims to raise 175.022 million yuan, reporting a net profit of 70.965 million yuan [2][25]. Fundraising Adjustments - Guoliang New Materials reduced its fundraising target from 301 million yuan to 175 million yuan, eliminating the R&D center project and adjusting working capital needs [3]. Financial Performance - Qilong Ocean reported total assets of 432.166 million yuan and a net profit of 49.075 million yuan for the first half of 2025 [7]. - Zhixin Co., Ltd. had total assets of 427.830 million yuan and a net profit of 9.448 million yuan for the first half of 2025 [12]. - Shaanxi Tourism's total assets reached 214.426 million yuan with a net profit of 24.707 million yuan for the first half of 2025 [17]. - Haiseng Medical reported total assets of 519.449 million yuan and a net profit of 35.494 million yuan for the first half of 2025 [23]. - Guoliang New Materials had total assets of 1.520 billion yuan and a net profit of 41.497 million yuan for the first half of 2025 [26]. Investment Projects - Qilong Ocean's main investment project is the high-performance large-diameter riser pipe production project, with a total investment of 381.889 million yuan [9]. - Zhixin Co., Ltd. plans to expand its production capacity and technology for automotive welding components, with a total investment of 1.329 billion yuan [13]. - Shaanxi Tourism's investment projects include the construction of various tourism facilities, totaling 1.555 billion yuan [19]. - Haiseng Medical's investment projects focus on upgrading and expanding production capabilities for anesthesia and monitoring medical devices, with a total investment of 482.701 million yuan [24]. - Guoliang New Materials is involved in high-temperature industrial refractory materials, with a total investment of 175.022 million yuan for its projects [27].

Core Viewpoint - Hebei Guoliang New Materials Co., Ltd. plans to raise CNY 300.68 million for various projects, including technology upgrades and new production lines [1][3]. Fundraising Projects - The company intends to invest in five key projects: 1. **Slab Water Outlet Production Line Technology Upgrade**: Total investment of CNY 36.49 million, with the same amount raised [3]. 2. **Annual Production of 50,000 Tons of Magnesium Carbon Brick Intelligent Manufacturing Project**: Total investment of CNY 84.42 million, with the same amount raised [3]. 3. **Annual Production of 150,000 Tons of Recycled Materials for Refractory Use**: Total investment of CNY 24.11 million, with the same amount raised [3]. 4. **Research and Development Center Construction Project**: Total investment of CNY 65.66 million, with the same amount raised [3]. 5. **Supplementing Working Capital**: Total investment of CNY 90 million, with the same amount raised [3]. Shareholding Structure - As of the signing date of the prospectus, Dong Guoliang holds 41,419,206 shares, accounting for 63.15% of the total share capital, while Zhao Sulan holds 5,799,330 shares, accounting for 8.84% [4]. - Together, they control 71.99% of the shares and 80.22% of the voting rights, making them the actual controllers of the company [4].

(责任编辑：宋政 HN002) 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com 格隆汇10月31日｜据界面，国内服务器龙头超聚变正在积极筹备上市相关工作。多个招聘网站的信息显 示，超聚变近期放出了"财务专家(上市运作)"岗位(目前该岗位已更名)。该岗位信息显示，候选人须具 备上市企业财务管理经验，曾直接参与上市公司年报、季报发布及合并财务报表等工作，并熟悉上市公 司体系建立及财务系统管理。另从超聚变内部了解，今年9月，公司再次开启了一轮针对核心员工的大 规模配股。 ...

浙江杭可科技股份有限公司 关于完成换届选举暨聘任高级管理人员的公告 38岁傅风华先生，已入职宇树科技，负责IPO相关事项。 走至IPO前夕的宇树，站在赛道"聚光灯"下。 近期，宇树科技在管理层层面动作频频，明显呈现出为上市冲刺的节奏。 据智通财经近日报道，杭可科技(688006.SH)原副总经理、财务总监兼董秘傅风华，已正式加盟宇树科技，负责公司IPO相关事务。 今年5月份，杭可科技发布《关于完成换届选举暨聘任高级管理人员的公告》，公告显示，傅风华先生不再担任公司董事会秘书、财务总监、副总经理。 证券代码:688006 证券简称:杭可科技 公告编号:2025-025 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 根据《中华人民共和国公司法》《上海证券交易所科创板股票上市规则》《上 海证券交易所科创板上市公司自律监管规则适用指引第1 号 -- 规范运作》以及 《浙江杭可科技股份有限公司章程》(以下简称"《公司章程》")的有关规定,浙 江杭可科技股份有限公司(以下简称"公司")分别于2025年5月19日、4 月 25 日召开 2 ...

Core Insights - SANY Heavy Industry Co., Ltd. successfully listed on the Hong Kong Stock Exchange on October 28, 2025, under the stock codes 6031.HK and 600031.SH [2] - Ernst & Young acted as the reporting accountant, overcoming various pressures to ensure a smooth listing process, receiving high recognition for their efforts [2] Company Overview - SANY Heavy Industry is a leading global player in the engineering machinery sector, focusing on the research, manufacturing, sales, and service of a full range of construction machinery products, including excavators, concrete machinery, cranes, pile machinery, and road machinery [3] - Based on cumulative revenue from core engineering machinery products from 2020 to 2024, SANY Heavy Industry ranks as the third largest globally and the largest in China [3] - The company's products are sold in over 150 countries and regions worldwide, participating in significant global projects such as the Hong Kong-Zhuhai-Macao Bridge, London Olympic venues, Burj Khalifa, and Beijing Olympic venues [3]

Core Insights - The 10th Pharmaceutical Innovation and Investment Conference was held in Nanjing, co-hosted by the China Pharmaceutical Innovation Promotion Association and the Hong Kong Stock Exchange, focusing on opportunities and trends in China's pharmaceutical industry [2] - Ernst & Young has participated in this conference for the seventh time since 2018, co-hosting the Capital Market Forum, which discussed key topics such as the development trends in the healthcare industry and the dynamics of domestic and international listings [2][5] - The forum featured discussions on the challenges and opportunities for unprofitable innovative pharmaceutical companies following the reintroduction of the fifth set of standards for the Sci-Tech Innovation Board [5][6] Group 1: Capital Market Forum - The forum provided a platform for policy interpretation, experience sharing, and resource connection among participants from various sectors [2] - Discussions included the financing paths for unprofitable biotech companies and strategies for capturing market opportunities while enhancing internal capabilities [5] - Participants emphasized the importance of solid clinical data to achieve better performance in the capital market [6] Group 2: Tax and Regulatory Considerations - Tax regulatory scrutiny on large cross-border transactions in biotech firms has increased, prompting recommendations for early-stage global intellectual property arrangements to alleviate tax burdens [8] - Companies are advised to consider the implications of different accounting standards and listing rules when preparing for overseas listings, particularly in Hong Kong [10][12] Group 3: Financial Preparation for Listings - Financial preparation is critical for companies transitioning from A-share to Hong Kong listings, with a focus on ensuring consistency in financial disclosures [12] - The listing process is described as a comprehensive undertaking that requires meticulous planning across financial, legal, and operational aspects [12]

Group 1 - The Beijing Municipal Financial Work Committee and the local financial management bureau support eligible enterprises in the Beijing-Tianjin-Hebei region to list on the Beijing Stock Exchange and to be listed on the New Third Board [1] - As of October 29, there are 280 companies listed on the Beijing Stock Exchange and 6,050 companies on the New Third Board [1] - Among these, there are 34 companies from the Beijing-Tianjin-Hebei region listed and 987 companies registered on the New Third Board [1]